Vancomycin

Chemical formula: C₆₆H₇₅Cl₂N₉O₂₄  Molecular mass: 1,449.254 g/mol  PubChem compound: 14969

Therapeutic indications

Vancomycin is indicated for:

Complicated skin and soft tissue infections (cSSTI)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Soft tissue infection and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Clostridium difficile infection (CDI)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Vancomycin is indicated in all age groups for the treatment of Clostridium difficile infection (CDI).

Oral administration: consideration should be given to discontinuing proton pump inhibitors and anti-motility agents in line with local guidelines for Clostridium Difficile infection.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prophylaxis of infective endocarditis

Population group: only minors (0 - 18 years old) , adults (18 years old or older)

Preventive procedure and additionally
Infective endocarditis and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infective endocarditis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infective endocarditis and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Infection of bone
Infectious disorder of joint
and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia (CAP), hospital acquired pneumonia (HAP)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Community acquired pneumonia
Nosocomial pneumonia
and additionally
Vancomycin susceptible species and additionally Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections (cSSTI)

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Soft tissue infection and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Clostridium difficile infection (CDI)

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Clostridium difficile infection
Clostridium difficile

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Community acquired pneumonia (CAP), hospital acquired pneumonia (HAP)

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Community acquired pneumonia
Nosocomial pneumonia
and additionally
Vancomycin susceptible species and additionally Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Infection of bone
Infectious disorder of joint
and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infective endocarditis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

Infective endocarditis and additionally at least one of
Vancomycin susceptible species
Vancomycin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: VANCOMYCIN Powder for solution for intravenous infusion / oral use
Structured Product Labeling (SPL/PLR) 2020: VANCOCIN Capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈